

SHORT  
COMMUNICATIONS

Dedicated to the Corresponding Member of the Russian Academy of Sciences  
B. V. Gidasov on occasion of his 60th anniversary

## 3H-Pyrido[6,7-*b*]-1,3,4-triazepines from 5-Aryltetrazoles

V. V. Nikulin, T. V. Artamonova, and G. I. Koldobskii

St. Petersburg State Technological Institute, St. Petersburg, 190013 Russia


Received December 20, 2002

The study of thermal transformation of *N*-imidoyltetrazoles generated under conditions of phase-transfer catalysis from 5-substituted tetrazoles and *N*-arylbenzimidoyl chlorides resulted in development of a new preparation method for previously unavailable 3*H*-1,3,4-benzotriazepines [1-7].

We have shown by numerous examples that the method is of general character and can be used for building up complex heterocyclic systems including several triazepine rings [5, 6]. However up till now


remained unclear whether this approach is suitable for triazepines synthesis with triazepine ring fused not to a benzene but to pyridine ring.

We report below on the new data showing the possibility to prepare by this procedure triazepines fused with a pyridine ring. We found that thermolysis of *N*-imidoyltetrazoles obtained under conditions of the phase-transfer catalysis from 5-aryltetrazoles and *N*-(*m*-pyridyl)benzimidoyl chloride gave rise to previously unknown 3*H*-pyrido[6,7-*b*]-1,3,4-triazepines.




R = R' = H (a), R = 4-Br, R' = H (b), R = 4-Cl, R' = H (c), R = H, R' = 4-Me (d).

3*H*-Pyrido[6,7-*b*]-1,3,4-triazepines (**Ia-d**), as also 3*H*-1,3,4-benzotriazepines [2, 5], are stable against bases but are easily hydrolyzed in water solutions of mineral acids.



At treatment of reagent **Ia** with methyl iodide in the presence of potassium *tert*-butylate arises the corresponding *N*-methyl derivative.



### 2,5-Diphenyl-3*H*-pyrido[6,7-*b*]-1,3,4-triazepine

(**Ia**). To a mixture of 0.01 mol of 5-phenyltetrazole, 0.001 mol of tetrabutylammonium bromide, 10 ml of 10% water solution of NaOH, and 30 ml of chloroform was added at 20°C while stirring within 30 min 0.01 mol of *N*-(*m*-pyridyl)benzimidoyl chloride in 10 ml of chloroform. The reaction mixture was stirred for 4 h at 20°C, the phases were separated, the organic layer was washed with 1% water solution of NaOH, with water (2-10 ml), and dried with magnesium sulfate. The chloroform was removed in a vacuum, to the solid residue was added 20 ml of toluene, and it was heated for 3 h to 110°C. Then the toluene was removed in a vacuum, the residue was recrystallized from acetonitrile. Yield 1.35 g (57%). After additional purification by column chromatography on silica gel (eluent carbon tetra-

chloride-ethyl acetate, 3:2) mp 205–208°C. IR spectrum,  $\text{cm}^{-1}$ : 926, 984, 1001, 1026, 1055, 1076, 1121, 1167.

**5-(4-Bromophenyl)-2-phenyl-3H-pyrido-[6,7-b]-1,3,4-triazepine (Ib).** Yield 17%. mp 221–222°C. IR spectrum,  $\text{cm}^{-1}$ : 935, 950, 990, 1020, 1035, 1075, 1120, 1170, 1180, 1230, 1270, 1290, 1325, 1390, 1450, 1475, 1495, 1565, 1600, 1635, 2865, 2935, 3085, 3335.  $^1\text{H}$  NMR spectrum (DMSO- $d_6$ ),  $\delta$ , ppm: 7.3–8.4 m (12H arom) 9.5 s (1H, NH). Found, %: C 60.49; H 3.27; N 14.87.  $\text{C}_{19}\text{H}_{13}\text{BrN}_4$ . Calculated, %: C 60.48; H 3.45; N 14.85.

**2-Phenyl-5-(4-chlorophenyl)-3H-pyrido-[6,7-b]-1,3,4-triazepine (Ic).** Yield 31%. mp 204–208°C. IR spectrum,  $\text{cm}^{-1}$ : 925, 950, 990, 1010, 1020, 1035, 1060, 1080, 1095, 1120, 1170, 1185, 1240, 1275, 1295, 1330, 1400, 1450, 1475, 1495, 1560, 1585, 1605, 1640, 2865, 2935, 3085, 3350.  $^1\text{H}$  NMR spectrum (DMSO- $d_6$ ),  $\delta$ , ppm: 7.3–8.4 m (12H arom), 9.0 s (1H, NH). Found, %: C 68.63; H 4.05; N 16.72.  $\text{C}_{19}\text{H}_{13}\text{ClN}_4$ . Calculated, %: C 68.57; H 3.91; N 16.84.

**2-(4-Tolyl)-5-phenyl-3H-pyrido[6,7-b]-1,3,4-triazepine (Id).** Yield 25%. mp 212–213°C. IR spectrum,  $\text{cm}^{-1}$ : 930, 950, 985, 1010, 1025, 1040, 1060, 1085, 1095, 1120, 1170, 1180, 1200, 1220, 1235, 1280, 1295, 1320, 1330, 1400, 1415, 1455, 1475, 1505, 1525, 1565, 1605, 1735, 2870, 2940, 3045, 3065, 3350.  $^1\text{H}$  NMR spectrum (DMSO- $d_6$ ),  $\delta$ , ppm: 2.4 s (3H  $\text{CH}_3$ ), 7.2–8.2 m (12H arom), 9.4 s (1H, NH). Found, %: C 77.01; H 5.27; N 17.93.  $\text{C}_{20}\text{H}_{16}\text{N}_4$ . Calculated, %: C 76.92; H 5.13; N 17.95.

**Acid hydrolysis of 2,5-diphenyl-3H-pyrido-[6,7-b]-1,3,4-triazepine (Ia).** A mixture of 1.2 mmol of triazepine **Ia**, 10 ml of 17% hydrochloric acid was heated for 2 h to 100°C, cooled to 5°C, the separated precipitate of benzoic acid was filtered off to obtain 0.058 g (40%) of benzoic acid, mp 123°C. To the filtrate was added 10% water solution of NaOH till pH 10–12, the separated precipitate was filtered off, washed with water (10 ml), and dried in air to obtain 0.212 g (89%) of 3-amino-2-benzylpyridine, mp 99–101°C (from hexane) [8].

**2,5-Diphenyl-1-methylpyrido[6,7-b]-1,3,4-triazepine.** To a solution of 1.7 mmol of reagent **Ia** in 30 ml of anhydrous tetrahydrofuran was added 2 mmol of potassium *tert*-butylate. The reaction mixture was stirred for 30 min at 20°C, 2.5 mmol of methyl iodide was added thereto. The stirring was continued for 2 h at 20°C, 150 ml of water was added, and the separated precipitate was filtered off. Yield 0.334 g (63%), mp 198–200°C. IR spectrum,  $\text{cm}^{-1}$ : 920, 935, 950, 975, 990, 1010, 1025, 1045, 1060, 1080, 1090, 1140, 1165, 1180, 1190, 1240, 1260, 1280, 1315, 1330, 1440, 1450, 1475, 1495, 1550, 1580, 1595, 2835, 2870, 2930, 2960, 3005, 3035, 3070.  $^1\text{H}$  NMR spectrum (DMSO- $d_6$ ),  $\delta$ , ppm: 3.15 s (3H,  $\text{CH}_3$ ), 7.39–8.45 m (13H arom). Found, %: C 77.09; H 5.25; N 17.80.  $\text{C}_{20}\text{H}_{16}\text{N}_4$ . Calculated, %: C 76.92; H 5.13; N 17.95.

IR spectra were recorded on spectrometer UR-20 from KBr pellets,  $^1\text{H}$  NMR spectra were registered on spectrometer Bruker AC-200. The purity and homogeneity of compounds obtained was tested by TLC on Silufol UV-254 plates, eluent mixture of carbon tetrachloride and ethyl acetate, 3:2. The study was carried out under financial support of the Ministry of Education of Russian Federation (Federal Program "Integratsiya", grant no. I 0667).

## REFERENCES

1. Koldobskii, G.I., Nikonova, I.V., Zhivich, A.B., Ostrovskii, V.A., and Poplavskii, V.S., *Zh. Obshch. Khim.*, 1992, vol. 62, p. 194.
2. Ivanova, S.E. and Koldobskii, G.I., *Khim. Geterotsykl. Soed.*, 1993, p. 907.
3. Koldobskii, G., Ivanova, S., Nikonova, I., Zhivich, A., and Ostrovskii, V., *Acta Chem. Scand.*, 1994, vol. 48, p. 596.
4. Koldobskii, G.I. and Ivanova, S.E., *Zh. Org. Khim.*, 1995, vol. 31, p. 1601.
5. Artamonova, T.V. and Koldobskii, G.I., *Zh. Org. Khim.*, 1997, vol. 33, p. 1850.
6. Artamonova, T.V. and Koldobskii, G.I., *Zh. Org. Khim.*, 2000, vol. 36, p. 1749.
7. Morgenstern, O., *Pharmazie*, 2000, vol. 55, p. 871.
8. Littell, R. and Allen, D.S., *J. Med. Chem.*, 1965, vol. 8, p. 722.